“Symptomatic” melanoma brain metastases: A call for clear definitions and adoption of standardized tools
Émilie Le Rhun(University of Zurich), Reinhard Dummer(University Hospital of Zurich), Michael Weller(University Hospital of Zurich), James Larkin(Trinity College Dublin), Nelson S. Moss(Memorial Sloan Kettering Cancer Center), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Jing Li(Shanghai Jiao Tong University), Carey K. Anders(Duke University)
Cited by 18
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k